BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Company profile
Ticker
BDSI
Exchange
Website
CEO
Jeffrey Bailey
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MAS ACQUISITION XXIII CORP
SEC CIK
Corporate docs
Subsidiaries
Arius Pharmaceuticals, Inc. • Arius Two, Inc. ...
IRS number
352089858
BDSI stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
1 Apr 22
EFFECT
Notice of effectiveness
28 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Mar 22
POS AM
Prospectus update (post-effective amendment)
23 Mar 22
8-K
Termination of a Material Definitive Agreement
22 Mar 22
Transcripts
BDSI
Earnings call transcript
2021 Q3
3 Nov 21
BDSI
Earnings call transcript
2021 Q2
4 Aug 21
BDSI
Earnings call transcript
2021 Q1
6 May 21
BDSI
Earnings call transcript
2020 Q4
10 Mar 21
BDSI
Earnings call transcript
2020 Q3
5 Nov 20
BDSI
Earnings call transcript
2020 Q2
5 Aug 20
BDSI
Earnings call transcript
2020 Q1
7 May 20
BDSI
Earnings call transcript
2019 Q4
12 Mar 20
BDSI
Earnings call transcript
2019 Q3
12 Nov 19
BDSI
Earnings call transcript
2019 Q2
9 Aug 19
Latest ownership filings
Financial summary
Quarter (USD) | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 91.00 k |
Total shares | 29.20 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 29.20 k | $91.00 k |